Verrica Pharmaceuticals Inc.
VRCA
$6.84
$0.6310.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 37.16M | 35.58M | 30.83M | 14.70M | 7.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.16M | 35.58M | 30.83M | 14.70M | 7.18M |
| Cost of Revenue | 14.32M | 12.30M | 10.17M | 9.69M | 11.22M |
| Gross Profit | 22.84M | 23.28M | 20.66M | 5.01M | -4.04M |
| SG&A Expenses | 36.36M | 35.22M | 36.98M | 43.66M | 51.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.69M | 47.52M | 47.15M | 53.36M | 62.55M |
| Operating Income | -13.52M | -11.94M | -16.32M | -38.65M | -55.37M |
| Income Before Tax | -17.83M | -17.89M | -26.01M | -48.60M | -65.99M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.83 | -17.89 | -26.01 | -48.60 | -65.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.83M | -17.89M | -26.01M | -48.60M | -65.99M |
| EBIT | -13.52M | -11.94M | -16.32M | -38.65M | -55.37M |
| EBITDA | -13.06M | -11.45M | -15.76M | -37.95M | -54.53M |
| EPS Basic | -1.03 | -1.61 | -3.44 | -8.30 | -12.01 |
| Normalized Basic EPS | -0.57 | -0.93 | -2.14 | -5.18 | -7.50 |
| EPS Diluted | -1.04 | -1.61 | -3.45 | -8.30 | -12.02 |
| Normalized Diluted EPS | -0.57 | -0.93 | -2.14 | -5.18 | -7.50 |
| Average Basic Shares Outstanding | 54.39M | 42.57M | 35.19M | 30.38M | 25.55M |
| Average Diluted Shares Outstanding | 54.40M | 42.57M | 35.20M | 30.39M | 25.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |